Development of the ATAQ-IPF: a tool to assess quality of life in IPF

Swigris, Jeffrey J.; Wilson, Sandra R.; Green, Kathy E.; Sprunger, David; Brown, Kevin K.; Wamboldt, Frederick S.

doi:10.1186/1477-7525-8-77

Cited by 68 publications

(66 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By including all domains of interest, using the ATAQ-IPF alleviates the need to administer additional questionnaires (eg, dyspnea or cough indexes). 26 Ongoing research aims to further build the validity of the ATAQ-IPF for use as an outcome measure in IPF trials.…”

Section: Pros In Ipf Trialsmentioning

confidence: 99%

“…26,27 The SGRQ-I is an IPF-specifi c variation of the original SGRQ, developed by applying Rasch analysis to SGRQ response data acquired in a multinational trial. 4,27 In Rasch analysis, response data are fi t to a mathematical model, the results of which place instrument items and respondents on the same scale.…”

Section: Ipf-specific Instrumentsmentioning

confidence: 99%

“…26 The ATAQ-IPF is a multidimensional questionnaire consisting of 74 items that tap 13 domains, including breathlessness, cough, fatigue, independence, and emotional health. By including all domains of interest, using the ATAQ-IPF alleviates the need to administer additional questionnaires (eg, dyspnea or cough indexes).…”

Section: Pros In Ipf Trialsmentioning

confidence: 99%

See 2 more Smart Citations

Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research

Swigris

Fairclough

2012

Chest

View full text Add to dashboard Cite

P atient-reported outcomes (PROs) seek to ascertain information about patients' experiences from their own perspective. Administered as questionnaires or surveys and completed by patients themselves, PROs attempt to quantify a person's perception of things such as health status, symptoms, or quality of life (QOL). PROs can reveal information patients might not disclose spontaneously, 1 thus strengthening their voices in the often overwhelming realm of their disease.In idiopathic pulmonary fi brosis (IPF), PROs used in either patient-perspectives research settings or ther-

show abstract

Section: Pros In Ipf Trialsmentioning

confidence: 99%

Section: Ipf-specific Instrumentsmentioning

confidence: 99%

See 1 more Smart Citation

Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research

Swigris

Fairclough

2012

Chest

View full text Add to dashboard Cite

show abstract

“…Studies reporting HRQoL in people with IPF were eligible for inclusion if they used either generic preference-based measures or the SGRQ, which is a disease-specific instrument used in IPF. Other recently developed disease-specific instruments such as the St George's Respiratory Questionnaire IPF (SGRQ-I), 106 the 'A Tool to Assess QOL in IPF' (ATAQ-IPF) 107 and the King's Brief Interstitial Lung Disease (K-BILD) 108 measures were not eligible for inclusion as there are currently no methods to map results of these to utility measures required for economic evaluation. Data from any study designs were eligible for inclusion in the systematic review.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…This does not appear to have been used in trials to date. Other disease-specific instruments such as the ATAQ-IPF 107 and the K-BILD 108 have also recently been developed.…”

Section: Dyspnoeamentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Loveman

Copley

Colquitt

et al. 2015

Health Technology Assessment

View full text Add to dashboard Cite

BackgroundIdiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease that generally affects people over 60 years old. The main symptoms are shortness of breath and cough, and as the disease progresses there is a considerable impact on day-to-day life. Few treatments are currently available.ObjectivesTo conduct a systematic review of clinical effectiveness and an analysis of cost-effectiveness of treatments for IPF based on an economic model informed by systematic reviews of cost-effectiveness and quality of life.Data sourcesEleven electronic bibliographic databases, including MEDLINE, EMBASE, Web of Science, and The Cochrane Library and the Centre for Reviews and Dissemination databases, were searched from database inception to July 2013. Reference lists of relevant publications were also checked and experts consulted.MethodsTwo reviewers independently screened references for the systematic reviews, extracted and checked data from the included studies and appraised their risk of bias. An advisory group was consulted about the choice of interventions until consensus was reached about eligibility. A narrative review with meta-analysis was undertaken, and a network meta-analysis (NMA) was performed. A decision-analytic Markov model was developed to estimate cost-effectiveness of pharmacological treatments for IPF. Parameter values were obtained from NMA and systematic reviews. Univariate and probabilistic sensitivity analyses were undertaken. The model perspective is NHS and Personal Social Services, and discount rate is 3.5% for costs and health benefits.ResultsFourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine, threeN-acetylcysteine (NAC) (alone or in combination), four pirfenidone, one BIBF 1120, one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management programme. Study quality was generally good, with a low risk of bias. The current evidence suggests that some treatments appear to be clinically effective. The model base-case results show increased survival for five pharmacological treatments, compared with best supportive care, at increased cost. General recommendations cannot be made of their cost-effectiveness owing to limitations in the evidence base.LimitationsFew direct comparisons of treatments were identified. An indirect comparison through a NMA was performed; however, caution is recommended in the interpretation of these results. In relation to the economic model, there is an assumption that pharmacological treatments have a constant effect on the relative rate of per cent predicted forced vital capacity decline.ConclusionsFew interventions have any statistically significant effect on IPF and a lack of studies on palliative care approaches was identified. Research is required into the effects of symptom control interventions, in particular pulmonary rehabilitation and thalidomide. Other research priorities include a well-conducted randomised controlled trial on inhaled NAC therapy and an updated evidence synthesis once the results of ongoing studies are reported.Study registrationThis study is registered as PROSPERO CRD42012002116.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

Interstitial Lung Disease

Forrest

Peel

2012

Integrated Palliative Care of Respiratory Disease

View full text Add to dashboard Cite

Background: The pathological diagnosis of interstitial lung diseases (ILD) by surgical lung biopsy is important for clinical decision making. There is a need, however, to use serum markers for differentiating usual interstitial pneumonia (UIP) from other ILD. Surfactant protein (SP)-A, SP-D, KL-6, sialyl SSEA-1 (SLX), and sialyl Lewis a (CA19-9) are useful markers for the diagnosis and evaluation of activity of ILD. We have investigated the usefulness of these proteins as markers of UIP. Methods: Serum and bronchoalveolar lavage (BAL) fluid levels of the above five markers were measured in 57 patients with various forms of ILD (19 with UIP, 12 with non-specific interstitial pneumonia (NSIP), eight with bronchiolitis obliterans organising pneumonia (BOOP), and 10 with sarcoidosis), eight patients with the control disease (diffuse panbronchiolitis (DPB)), and nine healthy volunteers. Results: Serum levels of SPA , SP-D, and KL-6 in patients with UIP and NSIP were significantly higher than in healthy volunteers. In particular, the serum levels of SPA in patients with UIP were significantly higher than in patients with NSIP (p<0.0001, mean difference-58.3 ng/ml, 95% confidence interval-81.6 to-35.0), and BAL fluid levels of SP-D in patients with UIP were significantly lower than in patients with NSIP (p=0.01, mean difference 322.4 ng/ml, 95% confidence interval 79.3 to 565.5). Conclusion: Serum SPA levels may be clinically useful as a biomarker to differentiate between UIP and NSIP.

show abstract

Development of the ATAQ-IPF: a tool to assess quality of life in IPF

Cited by 68 publications

References 19 publications

Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research

Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Interstitial Lung Disease

Contact Info

Product

Resources

About